Splash Beverage Group partners with Lupvindol Biosciences to advance CannEpil through FDA veterinary pathway

SPLASH BEVERAGE GROUP, INC.

Collaboration targets companion-animal oncology and chronic pain management; canine applications are initial focus.
Lupvindol CEO Hunter Land, Ph.D., led development of first FDA-approved plant-derived cannabinoid medicine Epidiolex.
Global veterinary pain-management market valued at $2.6B in 2024, projected to reach $3.8B by 2030.
Splash retains ownership of data, IP, and commercialization rights; provides milestone-based funding.
Program aims for FDA Conditional Approval under Section 571 of FD&C Act; no assurance of approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.